University of North Carolina - Lineberger Comprehensive Cancer Center
Welcome,         Profile    Billing    Logout  
 15 Trials 
23 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Milowsky, Matthew
NCT05987241: Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder for Bladder Cancer Treatment, MODERN Study

Recruiting
2/3
1190
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, cfDNA or ctDNA Measurement, Cell-Free DNA/Circulating Tumor DNA Measurement, cfDNA/ctdDNA Measurement, cfDNA/ctDNA, cfDNA/ctDNA Measurement, Circulating Cell-Free DNA/Circulating Tumor-Derived DNA Measurement, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Nivolumab, ABP 206, BCD-263, BMS 936558, BMS-936558, BMS936558, CMAB819, MDX 1106, MDX-1106, MDX1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO 4538, ONO-4538, ONO4538, Opdivo, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Relatlimab, BMS 986016, BMS-986016, BMS986016, Immunoglobulin G4, Anti-(human Lymphocyte Activation Gene-3 Protein) (Human Heavy Chain), Disulfide with Human Light Chain, Dimer
National Cancer Institute (NCI)
Muscle Invasive Bladder Urothelial Carcinoma, Stage II Bladder Urothelial Carcinoma AJCC v6 and v7, Stage III Bladder Urothelial Carcinoma AJCC v6 and v7, Stage IV Bladder Urothelial Carcinoma AJCC v7
04/26
04/26
NCT03108261: Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations

Not yet recruiting
2
209
US
Laboratory Biomarker Analysis, Sapanisertib, INK-128, INK128, MLN-0128, MLN0128, TAK-228
Yale University, National Cancer Institute (NCI)
Metastatic Transitional Cell Carcinoma, Metastatic Urothelial Carcinoma, Recurrent Bladder Carcinoma, Stage III Bladder Urothelial Carcinoma, Stage IV Bladder Urothelial Carcinoma
12/18
12/20
NCT02690558: Phase 2 Study of Pembrolizumab in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy

Active, not recruiting
2
39
US
pembrolizumab, gemcitabine and cisplatin, Keytruda, MK-3475
UNC Lineberger Comprehensive Cancer Center, Merck Sharp & Dohme LLC
Bladder Cancer
07/20
01/26
WOOPS, NCT03978624: Window of Opportunity Study of Pembrolizumab Alone and in Combinations in Bladder Cancer

Active, not recruiting
2
20
US
Pembrolizumab, Keytruda, Entinostat, SNDX-275, MS-275
UNC Lineberger Comprehensive Cancer Center, Merck Sharp & Dohme LLC, Syndax Pharmaceuticals
Bladder Cancer
01/24
11/26
NCT04164082: Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer

Recruiting
2
161
US, RoW
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Cystoscopy, CS, Gemcitabine Hydrochloride, dFdCyd, Difluorodeoxycytidine Hydrochloride, Gemcitabine HCI, Gemzar, LY 188011, LY-188011, LY188011, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Pembrolizumab, BCD-201, GME 751, GME751, Keytruda, Lambrolizumab, MK 3475, MK-3475, MK3475, Pembrolizumab Biosimilar BCD-201, Pembrolizumab Biosimilar GME751, Pembrolizumab Biosimilar QL2107, Pembrolizumab Biosimilar RPH-075, QL2107, RPH 075, RPH-075, RPH075, SCH 900475, SCH-900475, SCH900475, Transurethral Resection of Bladder Tumor, Transurethral resection (TURBT), TURBT
National Cancer Institute (NCI)
Bladder Urothelial Carcinoma In Situ, Non-Muscle Invasive Bladder Urothelial Carcinoma, Stage 0a Bladder Cancer AJCC v8, Stage 0is Bladder Cancer AJCC v8, Stage I Bladder Cancer AJCC v8
03/25
03/25
NCT05634785: CD30 CAR for CD30+ NSGCT

Recruiting
2
18
US
ATLCAR.CD30 Cells, CAR.CD30 T cells, Cyclophosphamid, Cytoxan, Fludarabine, Fludara
UNC Lineberger Comprehensive Cancer Center, University Cancer Research Fund at Lineberger Comprehensive Cancer Center
Germ Cell Tumor, Nonseminomatous Germ Cell Tumor
12/26
12/26
ACR-368-201, NCT05548296: A Study of ACR-368 in Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma

Recruiting
1/2
390
US
ACR-368, prexasertib, Gemcitabine, OncoSignature
Acrivon Therapeutics, GOG Foundation
Platinum-resistant Ovarian Cancer, Endometrial Adenocarcinoma, Urothelial Carcinoma
07/26
12/27
FX-909-CLINPRO-1, NCT05929235: A Study of FX-909 in Patients With Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma

Recruiting
1
75
US
FX-909
Flare Therapeutics Inc.
Advanced Solid Tumors Cancer, Advanced Urothelial Carcinoma, Oral Drug Administration, Open Label
09/26
01/27
NCT02643043: UC-GENOME: Urothelial Cancer-GENOmic Analysis to iMprove Patient Outcomes and rEsearch

Completed
N/A
219
US
Biospecimen Collection
Matthew Milowsky, MD, Bladder Cancer Advocacy Network (BCAN®), Hoosier Cancer Research Network
Urothelial Carcinoma, Bladder Cancer, Urethral Cancer, Cancer of the Ureter
05/19
09/23
NCT05630131: ctDNA in Subjects With Muscle-invasive Bladder Cancer Treated With Trimodality Therapy

Active, not recruiting
N/A
20
US
UNC Lineberger Comprehensive Cancer Center
Bladder Cancer, Muscle-Invasive Bladder Carcinoma
04/25
04/25
NCT05612880: Physical Function During ARSI Treatment

Completed
N/A
24
US
androgen receptor signaling inhibitors, abiraterone, enzalutamide, darolutamide, apalutamide
UNC Lineberger Comprehensive Cancer Center
Advanced Prostate Carcinoma
11/24
11/24
Lee, Michael Kang-Yin
IIH EVOLVE, NCT05347147 / 2021-006664-24: A Trial to Determine the Efficacy and Safety of Presendin in IIH

Terminated
3
14
Europe, US, RoW
Presendin, Placebo
Invex Therapeutics Ltd., Premier Research Group plc, University Hospitals Birmingham Neuro Ophthalmology Reading Centre, Birmingham, UK, Iowa Visual Field Reading Centre, Iowa, USA
Idiopathic Intracranial Hypertension
09/23
10/23
PICASSO, NCT05611242: Proximal Internal Carotid Artery Acute Stroke Secondary to Tandem or Local Occlusion Thrombectomy Trial

Recruiting
3
404
US
MT+CAS with IV-AP, Thrombectomy, MT+CAS with PO-AP, MT+CAT with PO-AP
Mercy Health Ohio
Acute Ischemic Stroke
03/26
05/27
NCT05733611: RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC

Active, not recruiting
2
4
NA
RP2, RP3, atezolizumab, bevacizumab
Replimune Inc., Roche Pharma AG
Refractory Metastatic Colorectal Cancer, pMMR, MSS
01/27
03/27
NCT03977233: Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer

Recruiting
2
45
US
Oxaliplatin, Eloxatin, Leucovorin, folinic acid, Irinotecan Hydrochloride, Camptosar, 5-FU, Adrucil
UNC Lineberger Comprehensive Cancer Center
Pancreatic Ductal Adenocarcinoma (PDAC), Cancer of Pancreas, Pancreatic Cancer, Adult, Pancreas Adenocarcinoma, Pancreatic Neoplasms, Pancreatic Cancer Non-resectable, Pancreatic Cancer Resectable
07/27
01/30
NCT05176665: EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers

Recruiting
1/2
152
US, RoW
EMB-01, FIT-013a
Shanghai EpimAb Biotherapeutics Co., Ltd., Labcorp Corporation of America Holdings, Inc
Neoplasms, Neoplasm Metastasis, Metastatic Gastrointestinal Carcinoid Tumor
12/25
12/25
PERIO-03, NCT05607953: Pressure Enabled Intrapancreatic Delivery of SD-101 With Checkpoint Blockade for Locally Advanced Pancreatic Adenocarcinoma

Recruiting
1
60
US
SD-101, anti-PD-1
TriSalus Life Sciences, Inc.
Locally Advanced Pancreatic Adenocarcinoma
10/24
10/26
BIOSOLVE-IV, NCT02817802: BIOTRONIKS - Safety and Performance in de NOvo Lesion of NatiVE Coronary Arteries With Magmaris- Registry:

Active, not recruiting
N/A
2066
Europe, RoW
Magmaris
Biotronik AG
Coronary Artery Disease
07/20
10/25
VANGAS, NCT06211725: The -Trial. The Value of Neurofilament Light Chain and Glial Fibrillary Acid Protein in the Blood of Patients With Asymptomatic Carotid Artery Stenosis

Recruiting
N/A
200
Europe
Heinrich-Heine University, Duesseldorf
Carotid Artery Stenosis, Carotid Artery Stenosis Asymptomatic, Carotid Artery Diseases, Carotid Artery Plaque
01/25
01/25
NCT05189171: MicroOrganoSphere (MOS) Drug Screen Pilot Trial in Colorectal Cancer

Completed
N/A
46
US
MicroOrganoSphere (MOS) drug screen
Xilis, Inc.
Colorectal Neoplasms
11/23
03/24
Munoz, Rachel
NCT03606174: A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma

Hourglass Jul 2022 - Dec 2022 : Interim data from trial in combination with Opdivo for 2L/3L bladder cancer
Hourglass Jan 2021 - Dec 2021 : Additional data from trial in combination with nivolumab for 2L/3L bladder cancer
Checkmark From trial in combination with Opdivo for urothelial cancer at ESMO 2020
Sep 2020 - Sep 2020: From trial in combination with Opdivo for urothelial cancer at ESMO 2020
Checkmark From trial in combination with Opdivo for urothelial cancer at SITC 2019
More
Terminated
2
260
US
Sitravatinib, MGCD516, Nivolumab, Opdivo, Pembrolizumab, Keytruda, Enfortumab vedotin, Padcev
Mirati Therapeutics Inc.
Urothelial Carcinoma, Urothelial Carcinoma Bladder, Urothelial Carcinoma Ureter, Urothelial Carcinoma of the Renal Pelvis and Ureter, Urothelial Carcinoma Urethra
08/22
08/22
Mitowsky, Matthew
NCT02122172: Afatinib in Advanced Refractory Urothelial Cancer

Terminated
2
95
US
afatinib dimaleate, afatinib, BIBW 2992 MA2, Gilotrif, laboratory biomarker analysis
University of Chicago, National Cancer Institute (NCI)
Distal Urethral Cancer, Proximal Urethral Cancer, Recurrent Bladder Cancer, Recurrent Urethral Cancer, Stage III Bladder Cancer, Stage III Urethral Cancer, Stage IV Bladder Cancer, Stage IV Urethral Cancer, Ureter Cancer
04/24
04/24
Thomas, Anly
NCT02122172: Afatinib in Advanced Refractory Urothelial Cancer

Terminated
2
95
US
afatinib dimaleate, afatinib, BIBW 2992 MA2, Gilotrif, laboratory biomarker analysis
University of Chicago, National Cancer Institute (NCI)
Distal Urethral Cancer, Proximal Urethral Cancer, Recurrent Bladder Cancer, Recurrent Urethral Cancer, Stage III Bladder Cancer, Stage III Urethral Cancer, Stage IV Bladder Cancer, Stage IV Urethral Cancer, Ureter Cancer
04/24
04/24

Download Options